279 related articles for article (PubMed ID: 22037640)
21. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.
Mégarbane B; Marie N; Pirnay S; Borron SW; Gueye PN; Risède P; Monier C; Noble F; Baud FJ
Toxicol Appl Pharmacol; 2006 May; 212(3):256-67. PubMed ID: 16169027
[TBL] [Abstract][Full Text] [Related]
22. Novel κ-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation.
Zhang LS; Wang J; Chen JC; Tao YM; Wang YH; Xu XJ; Chen J; Xu YG; Xi T; Hu XW; Wang YJ; Liu JG
Acta Pharmacol Sin; 2015 May; 36(5):565-71. PubMed ID: 25816912
[TBL] [Abstract][Full Text] [Related]
23. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
24. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
25. Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene.
Clarke S; Chen Z; Hsu MS; Pintar J; Hill R; Kitchen I
Brain Res; 2001 Jul; 906(1-2):13-24. PubMed ID: 11430857
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive activity of a novel buprenorphine analogue.
Lattanzi R; Negri L; Schmidhammer H; Giannini E
Life Sci; 2002 Mar; 70(18):2177-85. PubMed ID: 12002809
[TBL] [Abstract][Full Text] [Related]
27. Buprenorphine: new pharmacological aspects.
Cowan A
Int J Clin Pract Suppl; 2003 Feb; (133):3-8; discussion 23-4. PubMed ID: 12665117
[TBL] [Abstract][Full Text] [Related]
28. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
29. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice.
Alhaddad H; Cisternino S; Declèves X; Tournier N; Schlatter J; Chiadmi F; Risède P; Smirnova M; Besengez C; Scherrmann JM; Baud FJ; Mégarbane B
Crit Care Med; 2012 Dec; 40(12):3215-23. PubMed ID: 22975888
[TBL] [Abstract][Full Text] [Related]
30. Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
Li JX; Becker GL; Traynor JR; Gong ZH; France CP
J Pharmacol Exp Ther; 2007 Apr; 321(1):227-36. PubMed ID: 17220427
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
[TBL] [Abstract][Full Text] [Related]
32. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.
McLaughlin JP; Nowak D; Sebastian A; Schultz AG; Archer S; Bidlack JM
Eur J Pharmacol; 1995 Dec; 294(1):201-6. PubMed ID: 8788432
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
[TBL] [Abstract][Full Text] [Related]
34. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
35. Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors.
Kamei J; Saitoh A; Suzuki T; Misawa M; Nagase H; Kasuya Y
Life Sci; 1995 Mar; 56(15):PL285-90. PubMed ID: 8614238
[TBL] [Abstract][Full Text] [Related]
36. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.
Moody DE; Fang WB; Lin SN; Weyant DM; Strom SC; Omiecinski CJ
Drug Metab Dispos; 2009 Dec; 37(12):2323-9. PubMed ID: 19773542
[TBL] [Abstract][Full Text] [Related]
37. The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.
Yi SP; Kong QH; Li YL; Pan CL; Yu J; Cui BQ; Wang YF; Wang GL; Zhou PL; Wang LL; Gong ZH; Su RB; Shen YH; Yu G; Chang KJ
Acta Pharmacol Sin; 2017 Jul; 38(7):977-989. PubMed ID: 28502978
[TBL] [Abstract][Full Text] [Related]
38. Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.
Grinnell SG; Ansonoff M; Marrone GF; Lu Z; Narayan A; Xu J; Rossi G; Majumdar S; Pan YX; Bassoni DL; Pintar J; Pasternak GW
Synapse; 2016 Oct; 70(10):395-407. PubMed ID: 27223691
[TBL] [Abstract][Full Text] [Related]
39. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
40. Capsaicin inhibits the in vitro binding of peptides selective for mu- and kappa-opioid, and nociceptin-receptors.
Wollemann M; Ioja E; Benyhe S
Brain Res Bull; 2008 Sep; 77(2-3):136-42. PubMed ID: 18588953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
